



i 2L UC — Time to next treatment




Patients who did not switch to new treatment within 3 years:

ADA 42.70% | GOL 41.20% | IFX 43.85% | TOF 55.73% | UST 69.42% | VDZ 49.86%



ii 2L UC — Time to inadequate response




Patients who did not have an event of inadequate response within 3 years:


ADA 25.24% | GOL 8.12% | IFX 19.41% | TOF 29.17% | UST 20.83% | VDZ 26.46%




iii 2L UC — TTIR component: Dose escalation



Number at risk



iv 2L UC — TTIR component: IBD-related hospitalizations



Number at risk

